Evotec has been granted a patent for compounds that inhibit the epithelial sodium channel (ENaC). These compounds are applicable in treating or preventing various respiratory, skin, and ocular diseases and conditions, as defined in the patent’s abstract and claims. GlobalData’s report on Evotec gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Evotec, NSAID cancer drugs was a key innovation area identified from patents. Evotec's grant share as of July 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
The patent US12037336B2 encompasses a novel compound characterized by a specific chemical formula (I) and its various forms, including tautomeric forms, enantiomers, isotopic variants, and salts. The claims detail the structural components of the compound, particularly focusing on substituents such as R1, R10, and L1, which can include a range of functional groups and moieties. The patent outlines specific configurations for these substituents, including various alkyl, halo, and carboxyl groups, as well as complex structures involving nitrogen-containing heterocycles. Additionally, the claims specify methods for synthesizing these compounds and their potential applications in treating respiratory, skin, and ocular conditions.
The therapeutic applications highlighted in the patent include the treatment of diseases such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, and skin conditions like psoriasis. The patent also describes pharmaceutical compositions that incorporate the claimed compounds, which can be formulated for various routes of administration, including inhalation and buccal delivery. Furthermore, the compositions may include additional active agents, such as ß2 adrenoreceptor agonists, antihistamines, corticosteroids, and antibiotics, enhancing their therapeutic efficacy. The patent thus presents a comprehensive framework for the development of new therapeutic agents targeting a range of medical conditions.
To know more about GlobalData’s detailed insights on Evotec, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
